Fulgent Genetics (FLGT) Revenue & Revenue Breakdown
Fulgent Genetics Revenue Highlights
Latest Revenue (Y)
$322.67M
Latest Revenue (Q)
$85.39M
Main Segment (Y)
Laboratory Services
Main Geography (Y)
US
Fulgent Genetics Revenue by Period
Fulgent Genetics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $322.67M | 13.83% |
| 2024-12-31 | $283.47M | -1.99% |
| 2023-12-31 | $289.21M | -53.27% |
| 2022-12-31 | $618.97M | -37.64% |
| 2021-12-31 | $992.58M | 135.37% |
| 2020-12-31 | $421.71M | 1196.46% |
| 2019-12-31 | $32.53M | 52.31% |
| 2018-12-31 | $21.36M | 14.03% |
| 2017-12-31 | $18.73M | 2.48% |
| 2016-12-31 | $18.28M | 90.85% |
| 2015-12-31 | $9.58M | 649.30% |
| 2014-12-31 | $1.28M | 100.00% |
| 2001-12-31 | - | - |
Fulgent Genetics generated $322.67M in revenue during NA 2025, up 13.83% compared to the previous quarter, and up 76.51% compared to the same period a year ago.
Fulgent Genetics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-06-30 | $85.39M | 20.03% |
| 2026-03-31 | $71.14M | -14.64% |
| 2025-12-31 | $83.34M | -0.87% |
| 2025-09-30 | $84.07M | 2.77% |
| 2025-06-30 | $81.80M | 11.35% |
| 2025-03-31 | $73.46M | -3.61% |
| 2024-12-31 | $76.21M | 6.23% |
| 2024-09-30 | $71.74M | 1.01% |
| 2024-06-30 | $71.03M | 10.15% |
| 2024-03-31 | $64.48M | -8.54% |
| 2023-12-31 | $70.50M | -16.75% |
| 2023-09-30 | $84.69M | 24.81% |
| 2023-06-30 | $67.85M | 2.55% |
| 2023-03-31 | $66.17M | -2.27% |
| 2022-12-31 | $67.70M | -35.92% |
| 2022-09-30 | $105.66M | -15.71% |
| 2022-06-30 | $125.34M | -60.86% |
| 2022-03-31 | $320.27M | 27.26% |
| 2021-12-31 | $251.67M | 10.45% |
| 2021-09-30 | $227.87M | 48.34% |
| 2021-06-30 | $153.62M | -57.26% |
| 2021-03-31 | $359.43M | 21.85% |
| 2020-12-31 | $294.98M | 190.00% |
| 2020-09-30 | $101.72M | 489.15% |
| 2020-06-30 | $17.27M | 122.69% |
| 2020-03-31 | $7.75M | -7.56% |
| 2019-12-31 | $8.39M | -18.94% |
| 2019-09-30 | $10.35M | 22.83% |
| 2019-06-30 | $8.42M | 56.87% |
| 2019-03-31 | $5.37M | -5.44% |
| 2018-12-31 | $5.68M | 0.96% |
| 2018-09-30 | $5.63M | 4.17% |
| 2018-06-30 | $5.40M | 16.05% |
| 2018-03-31 | $4.65M | 8.69% |
| 2017-12-31 | $4.28M | -4.93% |
| 2017-09-30 | $4.50M | -2.95% |
| 2017-06-30 | $4.64M | -12.55% |
| 2017-03-31 | $5.31M | -9.36% |
| 2016-12-31 | $5.85M | 16.82% |
| 2016-09-30 | $5.01M | 26.19% |
| 2016-06-30 | $3.97M | 15.44% |
| 2016-03-31 | $3.44M | 18.58% |
| 2015-12-31 | $2.90M | -0.14% |
| 2015-09-30 | $2.90M | - |
Fulgent Genetics generated $85.39M in revenue during Q2 2026, up 20.03% compared to the previous quarter, and up 116.23% compared to the same period a year ago.
Fulgent Genetics Revenue Breakdown
Fulgent Genetics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 |
|---|---|---|
| Laboratory Services | $322.22M | $283.47M |
Fulgent Genetics's latest annual revenue breakdown by segment (product or service), as of Dec 25: Laboratory Services (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|
| Laboratory Services | $85.36M | $83.03M | $83.93M | $81.80M | $73.46M | $140.70M | $71.74M | $71.03M | - |
| Genetic Testing Services | - | - | - | - | - | - | - | - | $4.65M |
Fulgent Genetics's latest quarterly revenue breakdown by segment (product or service), as of Jun 26: Laboratory Services (100.00%).
Fulgent Genetics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 25 | Dec 24 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Non-US | $26.12M | $24.34M | - | - | - |
| Other Countries | $13.21M | $11.70M | $4.65M | $5.27M | - |
| US | $296.55M | - | - | - | - |
| CHINA | $12.91M | $12.64M | - | - | - |
| UNITED STATES | - | $259.13M | $978.98M | $415.33M | $25.01M |
| Non Us | - | - | $13.61M | - | - |
| CANADA | - | - | - | $1.73M | $2.25M |
Fulgent Genetics's latest annual revenue breakdown by geography, as of Dec 25: US (85.02%), Non-US (7.49%), Other Countries (3.79%), and CHINA (3.70%).
Quarterly Revenue by Country
| Country | Jun 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-US | $7.10M | $8.43M | $6.46M | $5.60M | $5.64M | $11.46M | $6.04M | $6.83M | - | - | - | - | - | - | - | - | - | - | - | - |
| CHINA | $3.08M | $4.76M | $3.13M | $2.41M | $2.61M | $7.38M | $2.79M | $2.48M | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Countries | $4.04M | $3.67M | $3.33M | $3.19M | $3.03M | $4.09M | $3.25M | $4.36M | $1.24M | $1.12M | $798.00K | $1.50M | $1.51M | $1.32M | $1.22M | $1.22M | - | - | - | - |
| UNITED STATES | $78.29M | $77.61M | $76.21M | $67.83M | $129.24M | $65.70M | $64.19M | $247.89M | $149.86M | $357.54M | $293.33M | $100.22M | $16.14M | $5.64M | $6.24M | $8.48M | $6.69M | $3.61M | - | - |
| Non Us | - | - | - | - | - | - | - | - | $3.78M | $4.18M | $3.75M | $1.89M | - | - | - | - | - | - | - | - |
| U S | - | - | - | - | - | - | - | - | - | $223.69M | - | - | - | - | - | - | - | - | - | - |
| CANADA | - | - | - | - | - | - | - | - | - | - | - | - | $401.00K | $376.00K | $329.00K | $619.00K | $643.00K | $548.00K | $516.00K | $538.00K |
Fulgent Genetics's latest quarterly revenue breakdown by geography, as of Jun 26: UNITED STATES (84.63%), Non-US (7.67%), Other Countries (4.37%), and CHINA (3.33%).
Fulgent Genetics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MYGN | Myriad Genetics | $824.50M | $190.70M |
| CDNA | CareDx | $379.81M | $131.95M |
| CSTL | Castle Biosciences | $344.23M | $103.55M |
| FLGT | Fulgent Genetics | $322.67M | $85.39M |
| ARVN | Arvinas | $262.60M | $249.70M |
| PACB | Pacific Biosciences of California | $160.00M | $39.01M |
| VALN | Valneva SE | $153.70M | $32.75M |
| BFLY | Butterfly Network | $97.61M | $29.02M |
| DRIO | DarioHealth | $22.36M | $5.18M |
| PSNL | Personalis | - | - |
| AVXL | Anavex Life Sciences | - | - |